Analysts expect Danaher Co. (NYSE:DHR) to announce earnings of $1.15 per share for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Danaher’s earnings. The lowest EPS estimate is $1.13 and the highest is $1.16. Danaher posted earnings of $1.10 per share in the same quarter last year, which would suggest a positive year over year growth rate of 4.5%. The firm is expected to report its next earnings report on Thursday, October 17th.
On average, analysts expect that Danaher will report full-year earnings of $4.79 per share for the current financial year, with EPS estimates ranging from $4.77 to $4.80. For the next financial year, analysts expect that the firm will post earnings of $5.49 per share, with EPS estimates ranging from $5.10 to $5.80. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Danaher.
Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, July 18th. The conglomerate reported $1.19 EPS for the quarter, topping the consensus estimate of $1.15 by $0.04. Danaher had a return on equity of 11.53% and a net margin of 12.22%. The business had revenue of $5.16 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the business posted $1.15 earnings per share. The company’s quarterly revenue was up 3.5% on a year-over-year basis.
In other news, insider Brian W. Ellis sold 1,010 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $144.04, for a total value of $145,480.40. Following the sale, the insider now directly owns 20,889 shares in the company, valued at $3,008,851.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Angela S. Lalor sold 20,000 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $142.30, for a total value of $2,846,000.00. Following the completion of the sale, the senior vice president now owns 58,515 shares in the company, valued at $8,326,684.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 361,850 shares of company stock worth $49,587,520. Insiders own 11.40% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Next Capital Management LLC acquired a new stake in shares of Danaher during the second quarter worth about $31,000. Litman Gregory Asset Management LLC purchased a new stake in Danaher in the 2nd quarter valued at approximately $33,000. Altshuler Shaham Ltd boosted its holdings in Danaher by 59.3% in the 2nd quarter. Altshuler Shaham Ltd now owns 239 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 89 shares in the last quarter. Lenox Wealth Management Inc. purchased a new stake in Danaher in the 1st quarter valued at approximately $40,000. Finally, MRA Associates USA LLC purchased a new stake in Danaher in the 2nd quarter valued at approximately $40,000. Institutional investors own 79.35% of the company’s stock.
Shares of DHR traded up $0.83 during midday trading on Thursday, hitting $137.19. 2,188,344 shares of the stock were exchanged, compared to its average volume of 2,612,125. Danaher has a 52-week low of $94.59 and a 52-week high of $145.50. The stock has a fifty day simple moving average of $141.39 and a 200 day simple moving average of $131.52. The firm has a market cap of $99.31 billion, a P/E ratio of 30.35, a P/E/G ratio of 2.50 and a beta of 0.94. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.91 and a current ratio of 2.32.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Recommended Story: Limitations of the P/E Growth ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.